620 results on '"Gupta, Abha"'
Search Results
2. Paediatric Strategy Forum for Medicinal Product Development of PI3-K, mTOR, AKT and GSK3β Inhibitors in Children and Adolescents with Cancer
3. Phase I Dose Escalation Study for In Vivo Lung Perfusion (IVLP) as an Adjuvant Treatment for Patients with Resectable Pulmonary Metastasis of Bone or Soft Tissue Sarcomas
4. The relationship between gamma-band neural oscillations and language skills in youth with Autism Spectrum Disorder and their first-degree relatives
5. Real-word experience of pazopanib and sorafenib in patients with desmoid tumors: A CanSaRCC multi-center study
6. Development of a flight simulator for lowend computers
7. Uncommon Mimicker of a High-Grade Thyroid Carcinoma: Solitary Thyroid Metastasis of Gastrointestinal Stromal Tumor (GIST)
8. Adapting an Adolescent and Young Adult Program Housed in a Quaternary Cancer Centre to a Regional Cancer Centre: Creating Equitable Access to Developmentally Tailored Support
9. Proximal discrepancies in intrinsic atomic interaction determines comparative in vivo biotoxicity of Chlorpyrifos and 3,5,6-trichloro-2-pyridinol in embryonic zebrafish
10. Unusual presentation of digital papillary adenocarcinoma in a sporotrichoid pattern
11. Parental Involvement in the Transition from Paediatric to Adult Care for Youth with Chronic Illness: A Scoping Review of the North American Literature
12. DISP-05. UNDERSTANDING THE INDIVIDUAL CHALLENGES AND EXPERIENCES OF YOUNG ADULTS WITH A DIAGNOSIS OF GLIOBLASTOMA AND HIGH-GRADE ASTROCYTOMA
13. Neuroligins
14. Candidate Genes in Autism
15. Chromosome 15q11–q13
16. Angelman/Prader-Willi Syndromes
17. Epicanthic Fold
18. Advanced Cancer in Young Adults (YAs): Living in a Liminal Space
19. Supplementary Table S3 from Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.
20. Supplementary Table S2 from Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.
21. Data from Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.
22. Supplementary Table S3 from Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.
23. Supplementary Table S1 from Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.
24. Data from Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.
25. Supplementary Figure S1 from Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.
26. Supplementary Figure S1 from Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.
27. Supplementary Table S1 from Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.
28. Supplementary Methods S1 from Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.
29. Supplementary Table S2 from Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.
30. Supplementary Methods S1 from Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma: Results of the DAPPER Clinical Trial.
31. Primary complex motor stereotypies are associated with de novo damaging DNA coding mutations that identify KDM5B as a risk gene
32. The impact of surgical resection margins on outcomes for adults with head and neck osteosarcomas: A Canadian sarcoma research and Clinical Collaboration (CanSaRCC) study
33. Real‐world experience of tyrosine kinase inhibitors in children, adolescents and adults with relapsed or refractory bone tumours: A Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) study
34. Safety, Immunologic, and Clinical Activity of Durvalumab in Combination with Olaparib or Cediranib in Advanced Leiomyosarcoma. Results of the DAPPER Clinical Trial.
35. Bibliometric Analysis on Influence of Behaviour Biases and Investment Decision Making
36. Common queries in managing rhabdomyosarcoma in low‐ and middle‐income countries: An Indo‐North American collaboration
37. Impact of Leadership Style and Happiness on Firm Performance
38. Genetics of autism spectrum disorders
39. Desmoid Fibromatosis and Dermatofibrosarcoma Protuberans
40. Retroperitoneal and Extremity Soft Tissue Sarcomas
41. Primitive Myxoid Mesenchymal Tumor of Infancy With Brain Metastasis Case Report and Literature Review
42. Feasibility of combining temsirolimus to vincristine, dactinomycin, cyclophosphamide, and vincristine and irinotecan chemotherapy for children with intermediate‐risk rhabdomyosarcoma: A report from Children's Oncology Group
43. Desmoid Tumors in Familial Adenomatous Polyposis Patients: Favorable Outcomes with Multidisciplinary Management
44. Radiation‐induced sarcomas following childhood cancer – A Canadian Sarcoma Research and Clinical Collaboration Study ( CanSaRCC )
45. Mesenchymal Tumors of the Breast: Fibroblastic/Myofibroblastic Lesions and Other Lesions
46. Data from Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions
47. Supplementary Table 3 from Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions
48. Supplementary Figure 2 from Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions
49. Supplementary Table 2 from Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions
50. Data from Inflammatory Myofibroblastic Tumors Harbor Multiple Potentially Actionable Kinase Fusions
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.